Journal of medical genetics · 2026
Location matters: topography of germline CEBPA variants predicts variable outcomes in familial acute myeloid leukaemia-a rare disease perspective.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Jinjun, Duan Xiaoqian, Zhu Min, Wu Yu
Аннотация
BACKGROUND: Familial acute myeloid leukaemia (AML) with germline CEBPA (CCAAT/enhancer-binding protein alpha) variants is a distinct hereditary entity, yet clinically meaningful genotype-phenotype correlations remain incompletely defined.
METHODS: We integrated cases from our institution with all published pedigrees of germline CEBPA-mutated AML and analysed 56 affected patients from 40 families, including one newly identified pedigree harbouring a novel TAD2 (transactivation domain 2) variant (p.C133Ter).
RESULTS: Variant localisation significantly influenced disease phenotype and outcome. Compared with non-TAD2 variants, TAD2 variants were associated with older age at AML onset (40 years vs 21 years, p<0.001), a higher burden of cooperating somatic variants (64.3% vs 27.3%, p=0.023) and lower complete remission rates after induction therapy (69.2% vs 95.3%, p=0.022). TAD2 involvement conferred inferior overall survival (p<0.001) and progression-free survival (p=0.025). In univariate analyses, TAD2 variants emerged as adverse prognostic factors for 2-year overall survival (OR=0.06, 95% CI 0.01 to 0.34, p=0.002) and progression-free survival (OR=0.07, 95% CI 0.01 to 0.35, p=0.003).
CONCLUSIONS: Although germline CEBPA-mutated AML is generally regarded as favourable-risk, TAD2-involving variants may define a biologically and clinically high-risk subset, supporting variant topography as a clinically actionable prognostic marker.
METHODS: We integrated cases from our institution with all published pedigrees of germline CEBPA-mutated AML and analysed 56 affected patients from 40 families, including one newly identified pedigree harbouring a novel TAD2 (transactivation domain 2) variant (p.C133Ter).
RESULTS: Variant localisation significantly influenced disease phenotype and outcome. Compared with non-TAD2 variants, TAD2 variants were associated with older age at AML onset (40 years vs 21 years, p<0.001), a higher burden of cooperating somatic variants (64.3% vs 27.3%, p=0.023) and lower complete remission rates after induction therapy (69.2% vs 95.3%, p=0.022). TAD2 involvement conferred inferior overall survival (p<0.001) and progression-free survival (p=0.025). In univariate analyses, TAD2 variants emerged as adverse prognostic factors for 2-year overall survival (OR=0.06, 95% CI 0.01 to 0.34, p=0.002) and progression-free survival (OR=0.07, 95% CI 0.01 to 0.35, p=0.003).
CONCLUSIONS: Although germline CEBPA-mutated AML is generally regarded as favourable-risk, TAD2-involving variants may define a biologically and clinically high-risk subset, supporting variant topography as a clinically actionable prognostic marker.